Foghorn Historical Income Statement

FHTX Stock

USD 7.79 0.27 3.59%

Historical analysis of Foghorn Therapeutics income statement accounts such as Depreciation And Amortization of 3.9 M or Interest Expense of 14 M can show how well Foghorn Therapeutics performed in making a profits. Evaluating Foghorn Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Foghorn Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Foghorn Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Foghorn Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Foghorn Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Foghorn Stock please use our How to Invest in Foghorn Therapeutics guide.

About Foghorn Income Statement Analysis

Foghorn Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Foghorn Therapeutics shareholders. The income statement also shows Foghorn investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Foghorn Therapeutics Income Statement Chart

At this time, Foghorn Therapeutics' Net Interest Income is fairly stable compared to the past year. Interest Income is likely to rise to about 11.1 M in 2024, whereas Selling General Administrative is likely to drop slightly above 19.7 M in 2024.

Selling General Administrative Other Operating Expenses Research Development Total Operating Expenses

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Foghorn Therapeutics. It is also known as Foghorn Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Total Operating Expenses

The total costs associated with the day-to-day operations of a business, excluding the cost of goods sold but including selling, general, and administrative expenses.

Most accounts from Foghorn Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Foghorn Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Foghorn Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.

For more information on how to buy Foghorn Stock please use our How to Invest in Foghorn Therapeutics guide.At this time, Foghorn Therapeutics' Net Interest Income is fairly stable compared to the past year. Interest Income is likely to rise to about 11.1 M in 2024, whereas Selling General Administrative is likely to drop slightly above 19.7 M in 2024.

	2021	2022	2023	2024 (projected)
Depreciation And Amortization	7.5M	3.3M	3.5M	3.9M
Interest Income	2.6M	5.7M	10.6M	11.1M

Depreciation And Amortization Interest Income

Foghorn Therapeutics income statement Correlations

	Net Interest Income	Interest Income	Depreciation And Amortization	Interest Expense	Selling General Administrative	Other Operating Expenses	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Ebitda	Total Operating Expenses	Reconciled Depreciation	Income Before Tax	Total Other Income Expense Net	Net Income	Income Tax Expense	Gross Profit	Cost Of Revenue	Non Operating Income Net Other	Selling And Marketing Expenses
Net Interest Income		0.99	0.42	0.98	0.81	0.8	-0.81	-0.8	-0.8	0.79	-0.81	0.8	0.75	-0.75	1.0	-0.77	0.87	-0.7	0.85	0.98	-0.88
Interest Income	0.99		0.51	0.97	0.84	0.84	-0.86	-0.84	-0.85	0.83	-0.86	0.84	0.8	-0.8	0.98	-0.82	0.9	-0.72	0.86	0.97	-0.88
Depreciation And Amortization	0.42	0.51		0.45	0.7	0.75	-0.82	-0.84	-0.83	0.77	-0.81	0.75	0.81	-0.86	0.35	-0.86	0.59	-0.49	0.49	0.41	-0.31
Interest Expense	0.98	0.97	0.45		0.87	0.86	-0.86	-0.84	-0.85	0.85	-0.86	0.86	0.8	-0.81	0.98	-0.81	0.78	-0.59	0.76	1.0	-0.79
Selling General Administrative	0.81	0.84	0.7	0.87		0.99	-0.95	-0.94	-0.94	0.98	-0.95	0.99	0.98	-0.93	0.79	-0.93	0.68	-0.45	0.59	0.85	-0.49
Other Operating Expenses	0.8	0.84	0.75	0.86	0.99		-0.97	-0.97	-0.97	1.0	-0.97	1.0	0.98	-0.96	0.77	-0.96	0.69	-0.49	0.62	0.84	-0.5
Operating Income	-0.81	-0.86	-0.82	-0.86	-0.95	-0.97		1.0	1.0	-0.97	1.0	-0.97	-0.96	1.0	-0.77	1.0	-0.74	0.53	-0.66	-0.84	0.6
Net Income From Continuing Ops	-0.8	-0.84	-0.84	-0.84	-0.94	-0.97	1.0		1.0	-0.97	1.0	-0.97	-0.96	1.0	-0.75	1.0	-0.75	0.54	-0.66	-0.82	0.59
Ebit	-0.8	-0.85	-0.83	-0.85	-0.94	-0.97	1.0	1.0		-0.97	1.0	-0.97	-0.96	1.0	-0.76	1.0	-0.74	0.53	-0.65	-0.82	0.58
Research Development	0.79	0.83	0.77	0.85	0.98	1.0	-0.97	-0.97	-0.97		-0.98	1.0	0.98	-0.97	0.76	-0.97	0.7	-0.5	0.62	0.83	-0.5
Ebitda	-0.81	-0.86	-0.81	-0.86	-0.95	-0.97	1.0	1.0	1.0	-0.98		-0.97	-0.96	0.99	-0.78	1.0	-0.74	0.53	-0.66	-0.84	0.6
Total Operating Expenses	0.8	0.84	0.75	0.86	0.99	1.0	-0.97	-0.97	-0.97	1.0	-0.97		0.98	-0.96	0.77	-0.96	0.69	-0.49	0.62	0.84	-0.5
Reconciled Depreciation	0.75	0.8	0.81	0.8	0.98	0.98	-0.96	-0.96	-0.96	0.98	-0.96	0.98		-0.96	0.71	-0.96	0.68	-0.43	0.56	0.78	-0.46
Income Before Tax	-0.75	-0.8	-0.86	-0.81	-0.93	-0.96	1.0	1.0	1.0	-0.97	0.99	-0.96	-0.96		-0.71	1.0	-0.7	0.49	-0.6	-0.78	0.53
Total Other Income Expense Net	1.0	0.98	0.35	0.98	0.79	0.77	-0.77	-0.75	-0.76	0.76	-0.78	0.77	0.71	-0.71		-0.72	0.82	-0.66	0.83	0.99	-0.87
Net Income	-0.77	-0.82	-0.86	-0.81	-0.93	-0.96	1.0	1.0	1.0	-0.97	1.0	-0.96	-0.96	1.0	-0.72		-0.72	0.51	-0.63	-0.79	0.55
Income Tax Expense	0.87	0.9	0.59	0.78	0.68	0.69	-0.74	-0.75	-0.74	0.7	-0.74	0.69	0.68	-0.7	0.82	-0.72		-0.87	0.93	0.77	-0.89
Gross Profit	-0.7	-0.72	-0.49	-0.59	-0.45	-0.49	0.53	0.54	0.53	-0.5	0.53	-0.49	-0.43	0.49	-0.66	0.51	-0.87		-0.97	-0.58	0.78
Cost Of Revenue	0.85	0.86	0.49	0.76	0.59	0.62	-0.66	-0.66	-0.65	0.62	-0.66	0.62	0.56	-0.6	0.83	-0.63	0.93	-0.97		0.76	-0.89
Non Operating Income Net Other	0.98	0.97	0.41	1.0	0.85	0.84	-0.84	-0.82	-0.82	0.83	-0.84	0.84	0.78	-0.78	0.99	-0.79	0.77	-0.58	0.76		-0.8
Selling And Marketing Expenses	-0.88	-0.88	-0.31	-0.79	-0.49	-0.5	0.6	0.59	0.58	-0.5	0.6	-0.5	-0.46	0.53	-0.87	0.55	-0.89	0.78	-0.89	-0.8

Click cells to compare fundamentals

Foghorn Therapeutics Account Relationship Matchups

Foghorn Therapeutics income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Net Interest Income	(45K)	22K	647K	5.7M	10.6M	11.1M
Interest Income	495K	1.0M	2.6M	5.7M	10.6M	11.1M
Depreciation And Amortization	1.2M	5.5M	7.5M	3.3M	3.5M	3.9M
Interest Expense	540K	979K	1.9M	11.6M	13.3M	14.0M
Selling General Administrative	6.7M	11.2M	21.7M	30.7M	32.4M	19.7M
Other Operating Expenses	51.1M	69.0M	102.1M	136.4M	142.1M	96.5M
Operating Income	(51.1M)	(68.5M)	(100.7M)	(117.1M)	(107.9M)	(113.3M)
Net Income From Continuing Ops	(51.1M)	(68.8M)	(101.3M)	(108.9M)	(103.2M)	(108.4M)
Ebit	(51.1M)	(72.0M)	(103.7M)	(117.1M)	(107.9M)	(113.3M)
Research Development	44.4M	57.7M	80.3M	105.6M	109.7M	76.8M
Ebitda	(49.9M)	(66.5M)	(96.2M)	(113.8M)	(104.5M)	(109.7M)
Total Operating Expenses	51.1M	69.0M	102.1M	136.4M	142.1M	96.5M
Reconciled Depreciation	693K	1.3M	3.2M	3.3M	3.4M	2.3M
Income Before Tax	(51.1M)	(68.8M)	(101.3M)	(108.9M)	(94.2M)	(98.9M)
Total Other Income Expense Net	(44K)	(269K)	(586K)	8.3M	13.7M	14.4M
Net Income Applicable To Common Shares	(51.1M)	(68.8M)	(101.3M)	(108.9M)	(98.0M)	(102.9M)
Net Income	(51.7M)	(69.8M)	(103.2M)	(108.9M)	(98.4M)	(103.3M)
Income Tax Expense	540K	979K	1.9M	(8.3K)	4.2M	4.4M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
GOOG	Alphabet Inc Class C
GOOG	Alphabet Inc Class C

Additional Tools for Foghorn Stock Analysis

When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Foghorn Historical Income Statement

About Foghorn Income Statement Analysis

Foghorn Therapeutics Income Statement Chart

Other Operating Expenses

Total Operating Expenses

Foghorn Therapeutics income statement Correlations

Foghorn Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Foghorn Therapeutics income statement Accounts

Also Currently Popular

Additional Tools for Foghorn Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Other Income Expense Net	+ 1.0	Net Interest Income
Non Operating Income Net Other	+ 1.0	Interest Expense
Research Development	+ 1.0	Other Operating Expenses
Total Operating Expenses	+ 1.0	Other Operating Expenses
Net Income From Continuing Ops	+ 1.0	Operating Income
Ebit	+ 1.0	Operating Income

Ebitda	- 0.98	Research Development
Cost Of Revenue	- 0.97	Gross Profit
Total Operating Expenses	- 0.97	Ebitda
Net Income	- 0.97	Research Development
Income Before Tax	- 0.97	Research Development
Total Operating Expenses	- 0.97	Ebit